Castle Biosciences
CSTL | NASDAQ
$32.75
-$1.04 (-3.08%)
At close: Nov 16, 2026, 4:00 PM ET
$32.75
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Castle Biosciences Company Profile
Company profile explainedCompany Profile
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Key Executives
| Name | Position |
|---|---|
| Derek J. Maetzold | Founder, Chief Executive Officer, President & Director |
| Frank Stokes | Chief Financial Officer & Treasurer |
| Kristen Oelschlager | Chief Operating Officer |
| Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs |
| Hillary Caruso | Chief of Staff |
| Jay Braxton | Senior Vice President of Marketing |
| Keli Greenberg | Vice President of Human Resources |
| Kevin Doman | Senior Vice President of Sales |
| Matthew Goldberg | Senior Vice President of Medical |
| Tobin W. Juvenal | Chief Commercial Officer |
| Trisha Poteet | Senior VP of Clinical Services & Manufacturing Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 28, 2026 | 4 | Filing |
| Oct 21, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
Castle Biosciences
| Country | United States |
| IPO Date | Jul 25, 2019 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,002 |
| CEO | Derek J. Maetzold |
Contact Details
1500 W. Parkwood Ave Friendswood,
Texas 77546 United States
Stock Details
| Ticker Symbol | CSTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001447362 |
| CUSIP Number | 14843C105 |
| ISIN Number | US14843C1053 |
| SIC Code | 8071 |
Recent News
- 4 days ago / prnewswire.comCastle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
- 5 days ago / prnewswire.comCastle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
- 5 days ago / prnewswire.comDecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
- 6 days ago / zacks.comWall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade
- 11 days ago / marketbeat.comWhat Castle Biosciences (CSTL) Said on Its Q3 Earnings Call
- 11 days ago / seekingalpha.comCastle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.comCastle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates
- 11 days ago / prnewswire.comCastle Biosciences Reports Third Quarter 2026 Results
- 20 days ago / prnewswire.comCastle Biosciences to Participate in Upcoming Investor Conferences
- 1 month ago / prnewswire.comCastle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
Add to Watchlist
Select watchlists to add or remove CSTL